Feasibility and outcome of interval debulking surgery (IDS) after carboplatin-paclitaxel-bevacizumab (CPB): A subgroup analysis of the MITO-16A-MaNGO OV2A phase 4 trial

Author:

Daniele GennaroORCID,Lorusso Domenica,Scambia Giovanni,Cecere Sabrina C.,Nicoletto Maria Ornella,Breda Enrico,Colombo Nicoletta,Artioli Grazia,Cannella Lucia,Lo Re Giovanni,Raspagliesi Francesco,Maltese Giuseppa,Salutari Vanda,Ferrandina Gabriella,Greggi Stefano,Baldoni Alessandra,Bergamini Alice,Piccirillo Maria Carmela,Tognon Germana,Floriani Irene,Signoriello Simona,Perrone Francesco,Pignata Sandro

Publisher

Elsevier BV

Subject

Obstetrics and Gynaecology,Oncology

Reference17 articles.

1. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet];Ferlay;In. Lyon, France: International Agency for Research on Cancer,2013

2. New biological treatments for gynecological tumors: focus on angiogenesis;Daniele;Expert. Opin. Biol. Ther.,2014

3. Incorporation of bevacizumab in the primary treatment of ovarian cancer;Burger;N. Engl. J. Med.,2011

4. A Phase 3 Trial of Bevacizumab in Ovarian Cancer

5. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer;Aghajanian;J. Clin. Oncol.,2012

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3